Clinical Trials
2
Active:1
Completed:1
Trial Phases
1 Phases
Phase 3:1
Drug Approvals
14
TGA:14
Drug Approvals
JINARC tolvaptan 30 mg + 60 mg tablet blister composite pack (272788)
- Product Name
- JINARC tolvaptan 30 mg + 60 mg tablet blister composite pack
- Approval Date
- Mar 24, 2017
TGA
JINARC tolvaptan 15 mg tablet blister pack (272785)
- Product Name
- JINARC tolvaptan 15 mg tablet blister pack
- Approval Date
- Mar 24, 2017
TGA
JINARC tolvaptan 15 mg + 45 mg tablet blister composite pack (272787)
- Product Name
- JINARC tolvaptan 15 mg + 45 mg tablet blister composite pack
- Approval Date
- Mar 24, 2017
TGA
JINARC tolvaptan 30 mg + 90 mg tablet blister composite pack (272789)
- Product Name
- JINARC tolvaptan 30 mg + 90 mg tablet blister composite pack
- Approval Date
- Mar 24, 2017
TGA
JINARC tolvaptan 30 mg tablet blister pack (272786)
- Product Name
- JINARC tolvaptan 30 mg tablet blister pack
- Approval Date
- Mar 24, 2017
TGA
SAMSCA tolvaptan 15 mg tablet blister pack (176602)
- Product Name
- SAMSCA tolvaptan 15 mg tablet blister pack
- Approval Date
- Apr 5, 2012
TGA
SAMSCA tolvaptan 30 mg tablet blister pack (176601)
- Product Name
- SAMSCA tolvaptan 30 mg tablet blister pack
- Approval Date
- Apr 5, 2012
TGA
BUSULFEX busulfan 60mg/10mL injection vial (150612)
- Product Name
- BUSULFEX busulfan 60mg/10mL injection vial
- Approval Date
- Jul 21, 2008
TGA
ABILIFY aripiprazole 20mg tablet blister pack (90999)
- Product Name
- ABILIFY aripiprazole 20mg tablet blister pack
- Approval Date
- May 21, 2003
TGA
ABILIFY aripiprazole 5mg tablet blister pack (90925)
- Product Name
- ABILIFY aripiprazole 5mg tablet blister pack
- Approval Date
- May 21, 2003
TGA
- Prev
- 1
- 2
- Next
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 3
1 (100.0%)A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia
Phase 3
Active, not recruiting
- Conditions
- Patient PreferenceLeukemia, Myelomonocytic, ChronicMyelodysplastic SyndromesLeukemia, Myeloid, Acute
- Interventions
- Drug: Oral decitabine/cedazuridine
- First Posted Date
- 2023-06-01
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- Otsuka Australia Pharmaceutical Pty Ltd
- Target Recruit Count
- 13
- Registration Number
- NCT05883956
- Locations
- 🇦🇺
Calvary Mater Newcastle, Newcastle, New South Wales, Australia
🇦🇺Pindara Private Hospital, Benowa, Queensland, Australia
🇦🇺Townsville Hospital, Townsville, Queensland, Australia
Refine and Assess the Readability of Patient, Carer, and Clinician Treatment Preference in Myelodysplasia Questionnaire
Completed
- Conditions
- Myelodysplastic Syndrome (MDS)
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Otsuka Australia Pharmaceutical Pty Ltd
- Target Recruit Count
- 16
- Registration Number
- NCT05817331
- Locations
- 🇦🇺
Calvary Mater Newcastle, Newcastle, New South Wales, Australia
News
No news found